| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $461,354 | 1 | 3 |
Sells | $3,296,177 | 29 | 97 |
| LINDSTROM RICHARD L MD | director | 1 | $461,354 | 0 | $0 | $461,354 |
| Anderman Todd | Chief Legal Officer | 0 | $0 | 1 | $87,363 | $-87,363 |
| Nayak Sanjay | Chief Strategy Officer | 0 | $0 | 5 | $166,407 | $-166,407 |
| Kaiser Peter | Chief Development Officer | 0 | $0 | 5 | $186,857 | $-186,857 |
| Heier Jeffrey S. | Chief Scientific Officer | 0 | $0 | 5 | $203,984 | $-203,984 |
| Notman Donald | Chief Operating Officer | 0 | $0 | 4 | $216,123 | $-216,123 |
| Waheed Nadia | Chief Medical Officer | 0 | $0 | 3 | $220,876 | $-220,876 |
| Saroj Namrata | Chief Business Officer | 0 | $0 | 1 | $277,790 | $-277,790 |
| Dugel Pravin | See Remarks | 0 | $0 | 5 | $1.94M | $-1.94M |
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and …
Over the last 12 months, insiders at Ocular Therapeutix, Inc. have bought $461,354 and sold $3.3M worth of Ocular Therapeutix, Inc. stock.
On average, over the past 5 years, insiders at Ocular Therapeutix, Inc. have bought $2.92M and sold $1.48M worth of stock each year.
Highest buying activity among insiders over the last 12 months: LINDSTROM RICHARD L MD (director) — $461,354.
The last purchase of 60,229 shares for transaction amount of $461,354 was made by LINDSTROM RICHARD L MD (director) on 2026‑02‑20.
| 2026-10-08 | Sale | Anderman Todd | Chief Legal Officer | 11,984 0.0052% | $7.29 | $87,363 | -8.85% | |
| 2026-10-02 | Sale | Heier Jeffrey S. | Chief Scientific Officer | 10,869 0.0049% | $7.05 | $76,626 | +1.80% | |
| 2026-10-02 | Sale | Kaiser Peter | Chief Development Officer | 9,990 0.0045% | $7.05 | $70,430 | +1.80% | |
| 2026-08-31 | Sale | Notman Donald | Chief Operating Officer | 1,099 0.0005% | $10.24 | $11,254 | -28.12% | |
| 2026-08-24 | Sale | Dugel Pravin | See Remarks | 21,649 0.0096% | $10.77 | $233,160 | -28.90% | |
| 2026-08-24 | Sale | Nayak Sanjay | Chief Strategy Officer | 1,897 0.0008% | $10.78 | $20,450 | -28.90% | |
| 2026-08-24 | Sale | Heier Jeffrey S. | Chief Scientific Officer | 3,296 0.0015% | $10.78 | $35,531 | -28.90% | |
| 2026-08-24 | Sale | Kaiser Peter | Chief Development Officer | 3,035 0.0013% | $10.77 | $32,687 | -28.90% | |
| 2026-06-03 | Sale | Waheed Nadia | Chief Medical Officer | 14,828 0.0067% | $8.27 | $122,628 | +10.36% | |
| 2026-05-26 | Sale | Dugel Pravin | See Remarks | 21,156 0.0093% | $8.20 | $173,479 | +9.53% | |
| 2026-05-26 | Sale | Nayak Sanjay | Chief Strategy Officer | 1,858 0.0008% | $8.20 | $15,236 | +9.53% | |
| 2026-05-26 | Sale | Heier Jeffrey S. | Chief Scientific Officer | 3,018 0.0013% | $8.20 | $24,748 | +9.53% | |
| 2026-05-26 | Sale | Kaiser Peter | Chief Development Officer | 2,967 0.0013% | $8.20 | $24,329 | +9.53% | |
| 2026-02-23 | Sale | Dugel Pravin | See Remarks | 20,056 0.0091% | $8.28 | $166,064 | +7.97% | |
| 2026-02-23 | Sale | Nayak Sanjay | Chief Strategy Officer | 1,759 0.0008% | $8.28 | $14,565 | +7.97% | |
| 2026-02-23 | Sale | Heier Jeffrey S. | Chief Scientific Officer | 3,057 0.0014% | $8.28 | $25,312 | +7.97% | |
| 2026-02-23 | Sale | Kaiser Peter | Chief Development Officer | 2,810 0.0013% | $8.28 | $23,267 | +7.97% | |
| 2026-02-20 | Sale | Waheed Nadia | Chief Medical Officer | 3,510 0.0016% | $7.74 | $27,167 | +15.81% | |
| 2026-02-20 | LINDSTROM RICHARD L MD | director | 60,229 0.0272% | $7.66 | $461,354 | +15.81% | ||
| 2026-02-12 | Sale | Dugel Pravin | See Remarks | 124,882 0.0572% | $9.04 | $1.13M | -1.05% |
| Notman Donald | Chief Operating Officer | 366529 0.1669% | $2.5M | 3 | 10 | +9.75% |
| Heier Jeffrey S. | Chief Scientific Officer | 307457 0.14% | $2.1M | 2 | 10 | +22.62% |
| LINDSTROM RICHARD L MD | director | 246933 0.1124% | $1.68M | 3 | 1 | +23.52% |
| SUMMER ROAD LLC | 10 percent owner | 8591401 3.912% | $58.59M | 31 | 0 | +18.95% |
| Opaleye Management Inc. | 10 percent owner | 4918500 2.2396% | $33.54M | 2 | 0 | +99.18% |
| CHV II, L.P. | 10 percent owner | 2100138 0.9563% | $14.32M | 1 | 0 | +69.82% |
| Sawhney Amarpreet | Chairman of the Board | 1056031 0.4809% | $7.2M | 10 | 0 | +25.15% |
| Mattessich Antony C. | President and CEO | 588701 0.2681% | $4.01M | 6 | 3 | +7.2% |
| Ankerud Eric | See Remarks | 78651 0.0358% | $536,399.82 | 1 | 0 | +69.82% |
| SVLSF IV, LLC | 10 percent owner | 61084 0.0278% | $416,592.88 | 1 | 1 | +69.82% |
| Bollag Daniel M | See Remarks | 42100 0.0192% | $287,122.00 | 2 | 0 | +12.45% |
| Goldstein Michael H. | Chief Medical Officer | 25686 0.0117% | $175,178.52 | 2 | 0 | +41.08% |
| Hanley Kevin F. | See Remarks | 20000 0.0091% | $136,400.00 | 2 | 0 | <0.0001% |
| Williams Leslie J. | director | 4500 0.002% | $30,690.00 | 1 | 0 | +3.43% |
$8,217,280 | 112 | 46.33% | $1.6B | |
$831,902,292 | 108 | 9.34% | $1.2B | |
Ocular Therapeutix, Inc. (OCUL) | $54,660,406 | 66 | 22.24% | $1.5B |
$530,111,731 | 35 | 8.69% | $1.51B | |
$27,136,525 | 32 | 36.73% | $1.64B |
| Increased Positions | 165 | +85.94% | 33M | +17.8% |
| Decreased Positions | 82 | -42.71% | 28M | -15.01% |
| New Positions | 60 | New | 9M | New |
| Sold Out Positions | 20 | Sold Out | 2M | Sold Out |
| Total Postitions | 275 | +43.23% | 192M | +2.79% |
| Fmr Llc | $375,706.00 | 14.92% | 31.79M | +12M | +62.1% | 2025-09-30 |
| Vr Adviser, Llc | $155,568.00 | 6.18% | 13.16M | +399,000 | +3.13% | 2025-09-30 |
| Summer Road Llc | $148,692.00 | 5.91% | 12.58M | -1M | -9.42% | 2025-09-30 |
| Deep Track Capital, Lp | $141,038.00 | 5.6% | 11.93M | -2M | -16.53% | 2025-09-30 |
| Blackrock, Inc. | $124,782.00 | 4.96% | 10.56M | +10,458 | +0.1% | 2025-09-30 |
| Avoro Capital Advisors Llc | $121,155.00 | 4.81% | 10.25M | +3M | +38.51% | 2025-09-30 |
| Vanguard Group Inc | $108,309.00 | 4.3% | 9.16M | +771,065 | +9.19% | 2025-09-30 |
| Tcg Crossover Management, Llc | $72,306.00 | 2.87% | 6.12M | +798,084 | +15% | 2025-09-30 |
| Citadel Advisors Llc | $67,419.00 | 2.68% | 5.7M | +817,767 | +16.74% | 2025-09-30 |
| Point72 Asset Management, L.P. | $54,388.00 | 2.16% | 4.6M | +3M | +141.64% | 2025-09-30 |